RESUMEN
Inclusion of compatible living donor and recipient pairs (CPs) in kidney paired donation (KPD) programs could increase living donor transplantation. We introduce the concept of a reciprocity-based strategy in which the recipient of a CP who participates in KPD receives priority for a repeat deceased donor transplant in the event their primary living donor KPD transplant fails, and then we review the practical and ethical considerations of this strategy. The strategy limits prioritization to CPs already committed to living donation, minimizing the risk of unduly influencing donor behavior. The provision of a tangible benefit independent of the CP's actual KPD match avoids many of the practical and ethical challenges with strategies that rely on finding the CP recipient a better-matched kidney that might provide the CP recipient a future benefit to increase KPD participation. Specifically, the strategy avoids the potential to misrepresent the degree of future benefit of a better-matched kidney to the CP recipient and minimizes delays in transplantation related to finding a better-matched kidney. Preliminary estimates suggest the strategy has significant potential to increase the number of living donor transplants. Further evaluation of the acceptance of this strategy by CPs and by waitlisted patients is warranted.
Asunto(s)
Selección de Donante , Rechazo de Injerto/prevención & control , Trasplante de Riñón/métodos , Donadores Vivos , Participación del Paciente , Obtención de Tejidos y Órganos/normas , Anciano , Muerte , Femenino , Rechazo de Injerto/etiología , Histocompatibilidad , Humanos , Trasplante de Riñón/efectos adversos , Masculino , Obtención de Tejidos y Órganos/métodosRESUMEN
Hypercalcemia, occurring in up to 25% of patients within 12 months following renal transplantation, and persistent hyperparathyroidism were evaluated following renal transplantation, by retrospective chart review of 1000 adult patients transplanted between January 1, 2003 and January 31, 2008 with at least six months follow-up. Serum calcium, parathyroid hormone, and phosphate levels were recorded at 12, 24, 36, and 48 months. Average follow-up was 766 (535) d (mean (SD); median 668 d). Majority were first transplants (85%); deceased donor 57%. Point prevalence of hypercalcemia (serum Ca(2+) > 2.6 mM) was 16.6% at month 12, 13.6% at month 24, 9.5% at month 36, and 10.1% at month 48. Point prevalence of serum parathyroid hormone (PTH) > 10 pM was 47.6% at month 12, 51.1% at month 24, 43.4% at month 36, and 39.3% at month 48. Estimated glomerular filtration rate (GFR) was maintained throughout and was not different between patients with or without hypercalcemia or elevated PTH. Cinacalcet was prescribed in 12% of patients with hypercalcemia and persistent hyperparathyroidism; parathyroidectomy was performed in 112/1000 patients, 15 post-transplant. Persistent hyperparathyroidism, often accompanied by hypercalcemia, is common following successful renal transplantation, but the lack of clear management suggests the need for further study and development of evidence-based guidelines.
Asunto(s)
Hipercalcemia/epidemiología , Hiperparatiroidismo/epidemiología , Fallo Renal Crónico/cirugía , Trasplante de Riñón/efectos adversos , Complicaciones Posoperatorias , Pautas de la Práctica en Medicina , Adulto , Canadá/epidemiología , Femenino , Estudios de Seguimiento , Tasa de Filtración Glomerular , Humanos , Hipercalcemia/etiología , Hiperparatiroidismo/etiología , Fallo Renal Crónico/complicaciones , Pruebas de Función Renal , Masculino , Persona de Mediana Edad , Prevalencia , Pronóstico , Estudios Retrospectivos , Factores de RiesgoRESUMEN
In kidney transplant recipients, cardiovascular disease (CVD) is the leading cause of death. The relationship of kidney function with CVD outcomes in transplant recipients remains uncertain. We performed a post hoc analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial to assess risk factors for CVD and mortality in kidney transplant recipients. Following adjustment for demographic, clinical and transplant characteristics, and traditional CVD risk factors, proportional hazards models were used to explore the association of estimated GFR with incident CVD and all-cause mortality. In 4016 participants, mean age was 52 years and 20% had prior CVD. Mean eGFR was 49 ± 18 mL/min/1.73 m(2) . In 3676 participants with complete data, there were 527 CVD events over a median of 3.8 years. Following adjustment, each 5 mL/min/1.73 m(2) higher eGFR at levels below 45 mL/min/1.73 m(2) was associated with a 15% lower risk of both CVD [HR = 0.85 (0.80, 0.90)] and death [HR = 0.85 (0.79, 0.90)], while there was no association between eGFR and outcomes at levels above 45 mL/min/1.73 m(2) . In conclusion, in stable kidney transplant recipients, lower eGFR is independently associated with adverse events, suggesting that reduced kidney function itself rather than preexisting comorbidity may lead to CVD.
Asunto(s)
Enfermedades Cardiovasculares/complicaciones , Pruebas de Función Renal , Trasplante de Riñón , Adulto , Anciano , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/fisiopatología , Creatinina/sangre , Femenino , Tasa de Filtración Glomerular , Humanos , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Factores de RiesgoRESUMEN
To explore the induction of monocyte/macrophage procoagulant activity in autoimmune disease, the BXSB murine model of systemic lupus erythematosus was studied. Splenic macrophage procoagulant activity rose coincident with age and the development of glomerulonephritis from 38 +/- 6 mU/10(6) macrophages at 1 mo to a maximum of 29,000 +/- 15,000 mU at 4 mo. Macrophages from 1-mo-old mice could be induced to express a 1,000-fold increase in monocyte/macrophage procoagulant activity when incubated with lymphocytes or lymphocyte supernatants from 5-mo-old mice. Plasma from 5-mo-old but not from 1-mo-old mice was able to induce the production of the lymphokine by cells from 1-mo-old animals. This lymphokine was not interleukin 1,2, or gamma interferon. We conclude that induction of monocyte/macrophage procoagulant activity parallels disease development in the male BXSB mouse, is dependent on the interaction between lymphocytes and plasma factors, and may be important in mediation of injury in lupus nephritis.
Asunto(s)
Factores de Coagulación Sanguínea/biosíntesis , Lupus Eritematoso Sistémico/metabolismo , Factores de Edad , Animales , Sangre , Linfocitos/metabolismo , Linfocinas/biosíntesis , Masculino , Ratones , Peso Molecular , Bazo/metabolismoRESUMEN
Monocyte infiltration and activation of the coagulation system have been implicated in the pathophysiology of glomerulonephritis. In this study, spontaneous procoagulant activity (PCA) was measured in circulating mononuclear cells to determine whether elevated PCA correlated with the presence of proliferative glomerulonephritis in patients with systemic lupus erythematosus (SLE). No increase in PCA was found in 20 patients with end-stage renal failure, 8 patients with glomerulonephritis without SLE, and 10 patients undergoing abdominal surgical or orthopedic procedures as compared with 20 normal controls. In eight patients with SLE but with no apparent active renal disease, PCA was not elevated above normal basal levels. Seven additional patients with SLE who had only mesangial proliferation on biopsy also had no increase in PCA. In contrast, eight patients with focal or diffuse proliferative lupus nephritis, and one patient with membranous nephritis who ultimately developed a proliferative lesion, had a marked increase in PCA with greater than 100 times the base-line levels. The activity was shown to originate in the monocyte fraction of the mononuclear cells and was shown to be capable of cleaving prothrombin directly. The prothrombinase activity was not Factor Xa, because it was not neutralized by anti-Factor X serum and was not inhibited by an established panel of Factor Xa inhibitors. Monocyte plasminogen activator determinations did not correlate with renal disease activity. We conclude that monocyte procoagulant activity, a direct prothrombinase, seems to correlate with endocapillary proliferation in lupus nephritis and could be a mediator of tissue injury.
Asunto(s)
Factores de Coagulación Sanguínea/metabolismo , Endopeptidasas , Precursores Enzimáticos , Glomerulonefritis/enzimología , Lupus Eritematoso Sistémico/enzimología , Monocitos/enzimología , Factores de Coagulación Sanguínea/biosíntesis , Pruebas de Coagulación Sanguínea , Glomerulonefritis/sangre , Glomerulonefritis/fisiopatología , Humanos , Hipoprotrombinemias/sangre , Riñón/patología , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/fisiopatología , Activadores Plasminogénicos/sangreRESUMEN
Currently the mechanism of renal allograft rejection is not well understood. This study was designed to determine whether induction of monocyte procoagulant activity (MCPA) is important in the pathogenesis of renal allograft rejection. The MPCA assay was performed utilizing a one stage clotting assay both in normal and in factor-VII-deficient plasma. There was no increase in spontaneous MPCA in 20 patients with endstage renal failure and in 10 patients following abdominal or orthopedic operation, as compared with 20 normal controls. MPCA was assessed daily in 18 patients who had received renal allografts. Rejection episodes (RE) were predicted on the basis of persistent elevation in MPCA as compared with pretransplant levels. Rejection was diagnosed clinically and treated on the basis of standard criteria. Treated RE were compared with those predicted by elevated MPCA, and 3 patients were assessed as having no RE by MPCA and by standard criteria. In 8 RE, MPCA correlated temporally with RE (same day) when compared with standard criteria. In 12 RE, MPCA was predictive of rejection preceding standard criteria by at least 24 hr. There were 7 false-positive predictions on the basis of MPCA; however, there was only 1 false negative. MPCA was shown to be a prothrombinase by its dependence only on prothrombin and fibrinogen for full activity. MPCA may be important in the pathogenesis of allograft rejection, and additionally it may be a useful adjunct in the clinical management of this disease.
Asunto(s)
Factores de Coagulación Sanguínea/inmunología , Rechazo de Injerto , Activadores Plasminogénicos/inmunología , Adulto , Creatinina/sangre , Reacciones Falso Positivas , Femenino , Humanos , Radioisótopos de Yodo , Fallo Renal Crónico/inmunología , Trasplante de Riñón , Masculino , Persona de Mediana Edad , Trasplante HomólogoRESUMEN
We examined the factors determining graft survival in 200 consecutive cadaveric renal transplants managed on a quadruple-therapy protocol: Minnesota antilymphoblast globulin, cyclosporine, azathioprine, and low-dose prednisone. Perioperative central venous pressure monitoring and volume expansion were emphasized. To avoid CsA nephrotoxicity in the early posttransplant period, patients were treated with ALG until renal function was established (a mean of 7 days). Therapeutic CsA levels were achieved before ALG was discontinued. Azathioprine was used to supplement CsA in patients with nephrotoxicity or rejection. Twelve-month graft survival was 85% (first transplants 86%, retransplants 79%), with patient survival of 95%. ALG was not associated with excessive clinical cytomegalovirus infections, which occurred in 5% of patients, or with malignancy. When 3 technical failures were excluded, an analysis of numerous factors in the pretransplant and peritransplant period revealed that the strongest correlate of one-year graft survival was early renal function. Grafts with delayed function (DF) had 75% survival, compared with 91% for grafts with good early function (EF). A multivariate analysis confirmed this association: the relative risk of graft loss was increased 2.86 times for DF compared with EF. The mechanism of the deleterious effect of DF was apparently multifactorial: the DF group, by definition, contained all the kidneys that never functioned, but some risk also persisted in kidneys that achieved function. One reason for this may be that DF kidneys that achieved function had higher mean serum creatinine values at 1 month: elevated serum creatinine values at 1 month were strongly associated with increased risk of graft loss regardless of initial function. There was also a higher number of rejection episodes diagnosed in the DF group. These observations suggest that early renal function is a major determinant of graft outcome and should be a target for efforts to further improve renal graft survival.
Asunto(s)
Supervivencia de Injerto , Trasplante de Riñón , Suero Antilinfocítico/uso terapéutico , Creatinina/sangre , Ciclosporinas/uso terapéutico , Humanos , Riñón/fisiología , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Factores de TiempoRESUMEN
A total 166 first cadaveric renal allograft recipients were randomly assigned to receive either rabbit antithymocyte serum (RATS) (n = 83) or OKT3 (n = 83) for 10 to 14 days after transplant as prophylaxis against rejection. Both groups were similar with respect to age, sex, donor age, diabetes, time on dialysis, panel-reactive antibody, HLA matching, and transfusion before transplantation. All patients were followed for 1 year after transplantation. A comparison of the rejection rates between the 2 groups of patients showed that patients receiving OKT3 had a rate of first rejection 1.87 times higher than those receiving RATS (95% confidence interval 1.18-2.8, P = 0.007). Twenty-five steroid-resistant rejections occurred in OKT3-treated patients as compared with 12 in the RATS-treated group (P < 0.05). There was no significant difference in early or late renal function between the 2 groups of patients. Actuarial 1-year graft survival for the RATS group was 78% and for the OKT3 group, 80.7% (P = NS). Actuarial 1-year patient survival was similar: 89.5% in the RATS group and 94.6% in the OKT3 group (P = NS). Total hospitalization time was 29.8 +/- 19.9 days for RATS vs. 39.5 +/- 22.1 days for those treated with OKT3 (P < 0.006). A number of infections were observed but there were no significant differences between the groups. We conclude that RATS provides better prophylaxis than OKT3 in first cadaveric renal transplants because it is associated with fewer rejection episodes, less hospitalization, and no additional morbidity or mortality.
Asunto(s)
Suero Antilinfocítico/uso terapéutico , Rechazo de Injerto/prevención & control , Terapia de Inmunosupresión/métodos , Trasplante de Riñón/métodos , Muromonab-CD3/uso terapéutico , Adulto , Anciano , Animales , Cadáver , Creatinina/sangre , Femenino , Supervivencia de Injerto , Humanos , Prueba de Cultivo Mixto de Linfocitos , Masculino , Persona de Mediana Edad , Conejos/inmunología , Factores de Riesgo , Análisis de Supervivencia , Factores de TiempoRESUMEN
BACKGROUND: A novel but controversial method to increase the utilization of aged donor kidneys is the transplantation of both kidneys as a dual transplant. Initial single-center reports demonstrated outcomes similar to single kidneys from younger donors. In this report, we compare outcome in recipients of kidneys from donors > or =54 years of age who received a single kidney transplant reported to the United Network for Organ Sharing Scientific Registry versus a dual kidney transplant reported to the Dual Kidney Registry. METHODS: A retrospective analysis was performed, comparing four donor and nine recipient and outcome variables between recipients of a single versus a dual transplant between March 1993 and March 1999. RESULTS: Dual versus single transplants from donors > or =54 years of age have a significantly decreased incidence of delayed graft function, and lower serum creatinines up to 2 years after transplant despite having kidneys from significantly older donors with poorer HLA matching. CONCLUSIONS: Dual kidney transplants improve graft performance and outcome in recipients of kidneys from donors > or =54 years of age.
Asunto(s)
Trasplante de Riñón , Donantes de Tejidos , Anciano , Humanos , Trasplante de Riñón/métodos , Trasplante de Riñón/fisiología , Persona de Mediana Edad , Sistema de Registros , Resultado del TratamientoRESUMEN
Coagulation remains a major barrier to successful xenotransplantation. Identification of the role of complement activation in HAR and prevention of complement activation by high expression of DAF and CD59 has largely overcome HAR. Understanding the molecular basis of DXR and identification of novel strategies to prevent activation of endothelial cells using monoclonal antibodies, soluble inhibitors of coagulation, vaccination, antisense constructs, and recombinant DNA technology offers the promise of overcoming the thrombosis associated with xenotransplantation.
Asunto(s)
Coagulación Sanguínea , Rechazo de Injerto/fisiopatología , Complicaciones Posoperatorias/prevención & control , Trombosis/prevención & control , Trasplante Heterólogo/efectos adversos , Trasplante Heterólogo/fisiología , Enfermedad Aguda , Animales , Anticuerpos Heterófilos/biosíntesis , Anticuerpos Monoclonales/uso terapéutico , Antígenos Heterófilos/inmunología , Endotelio Vascular/inmunología , Ingeniería Genética , Rechazo de Injerto/sangre , Rechazo de Injerto/prevención & control , Humanos , Ratones , Ratones Noqueados , ARN sin Sentido/uso terapéutico , Porcinos , Vacunas/uso terapéuticoAsunto(s)
Glucosa/metabolismo , Hiperglucemia/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Animales , Caprilatos/metabolismo , Dióxido de Carbono , Radioisótopos de Carbono , Cicloheximida/farmacología , Epinefrina/farmacología , Glucosa/administración & dosificación , Glucosa/antagonistas & inhibidores , Inyecciones Intravenosas , Secreción de Insulina , Islotes Pancreáticos/efectos de los fármacos , Masculino , Ouabaína/farmacología , Oxidación-Reducción , Puromicina/farmacología , Radioinmunoensayo , RatasAsunto(s)
Trasplante de Riñón , Proteinuria/etiología , Análisis Actuarial , Glomerulonefritis Membranoproliferativa/etiología , Glomeruloesclerosis Focal y Segmentaria/etiología , Glomeruloesclerosis Focal y Segmentaria/mortalidad , Rechazo de Injerto , Humanos , Pronóstico , Proteinuria/mortalidad , Proteinuria/patologíaAsunto(s)
Suero Antilinfocítico/uso terapéutico , Antígenos CD55/genética , Rechazo de Injerto/prevención & control , Inmunosupresores/uso terapéutico , Trasplante de Riñón/inmunología , Trasplante Heterólogo/inmunología , Animales , Animales Modificados Genéticamente , Antígenos CD/genética , Ciclofosfamida/uso terapéutico , Humanos , Papio , Conejos , PorcinosRESUMEN
A solitary native kidney is generally considered to be an absolute contraindication to percutaneous biopsy. However, technical advances, such as real-time ultrasound guidance and automated core biopsy systems, provide an excellent safety profile with an extremely low risk of catastrophic complications and have caused some investigators to call for a reassessment of this contraindication. The overall results at our institution are reported. Of 544 consecutive native and allograft kidney biopsies conducted over 2.5 years, 482 were performed with an automated core biopsy system and 281 also used real-time ultrasound guidance. The overall complication rate was 5.3%. Transient gross hematuria was seen in 4.4% and hematoma was seen in 1.5%; no patient experienced loss of kidney function and there were no deaths. We recently have begun to perform percutaneous biopsy of solitary native kidneys in carefully selected patients. To date, nine such procedures have been attempted, with success in eight cases. One patient had transient gross hematuria; no other complications were noted. This encouraging preliminary experience suggests that otherwise uncomplicated adult patients with a solitary kidney might be considered for percutaneous biopsy. It now seems appropriate to prospectively evaluate percutaneous biopsy of solitary kidneys in a larger cohort of unselected patients.